Qualigen Therapeutics, Inc. Announces management changes.
27 September 2024 - 7:10AM
Qualigen Therapeutics, Inc. (NASDAQ: QLGN) (the “Company”)
announced on September 23, 2024, Mr. Michael Poirier, notified the
board of directors of the Company (the Board") of his intention to
resign as chief executive officer and Chairman of the Board of the
Company, effective immediately. On the same date, Mr. Christopher
Lotz, Chief Financial Office also tendered his resignation from the
company, effective immediately. Both resignations were attributed
to disagreements with the Company regarding its future direction
and strategic initiatives.
On September 25, 2024, the board of directors
appointed Campbell Becher as President of the Company, effective
immediately.
On September 26, 2024, the board of directors
appointed Kevin Richardson as Interim Chief Executive Officer and
Chief Financial Officer as well as a member of the board of
directors. Mr. Richardson has extensive experience in leading
strategic and turnaround efforts in various small cap companies. “I
am excited to be given the opportunity to lead Qualigen as it
embarks on new strategic initiatives that will enhance shareholder
value”. Mr. Richardson most recently served as CEO of Sanuwave
Health Inc., a medical device startup that Mr. Richardson took from
a fledgling operation to $20mm in revenue.
New President Campbell Becher shares Mr.
Richardson’s enthusiasm for the future. “We are entering an
exciting time at Qualigen with many potential opportunities ahead.
We would like to thank Michael and Chris for their years of
leadership and guidance at Qualigen.”
About Qualigen Therapeutics,
Inc.
For more information about Qualigen
Therapeutics, Inc., please visit www.qlgntx.com.
Forward-Looking Statements
This news release contains “forward-looking
statements” within the meaning of Section 27A of the Securities Act
of 1933, as amended, and Section 21E of the Securities Exchange Act
of 1934, as amended. The Company may in some cases use terms such
as “predicts,” “believes,” “potential,” “continue,” “anticipates,”
“estimates,” “expects,” “plans,” “intends,” “may,” “could,”
“might,” “likely,” “will,” “should” or other words that convey
uncertainty of the future events or outcomes to identify these
forward-looking statements. The Company’s forward-looking
statements are based on current beliefs and expectations of its
management team that involve risks, potential changes in
circumstances, assumptions, and uncertainties, including statements
regarding the timing of the offering. Any or all of the
forward-looking statements may turn out to be wrong or be affected
by assumptions the Company makes that later turn out to be
incorrect, or by known or unknown risks and uncertainties. These
forward-looking statements are subject to risks and uncertainties
including risks related to the Company’s ability to regain
compliance with Nasdaq’s continued listing requirements, including
the Company’s ability to file its Form 10-Q for the period ended
September 30, 2024, or otherwise in the future, or otherwise
maintain compliance with any other listing requirement of The
Nasdaq Capital Market, the potential de-listing of the Company’s
shares from The Nasdaq Capital Market due to its failure to comply
with the Nasdaq’s continued listing requirement, or its
alternatives, or otherwise in the future, and the other risks set
forth in the Company’s filings with the Securities and Exchange
Commission, including in its Annual Reports on Form 10-K and its
Quarterly Reports on Form 10-Q. For all these reasons, actual
results and developments could be materially different from those
expressed in or implied by the Company’s forward-looking
statements. You are cautioned not to place undue reliance on these
forward-looking statements, which are made only as of the date of
this news release. The Company disclaims any intent or
obligation to update these forward-looking statements beyond the
date of this news release, except as required by law. This caution
is made under the safe harbor provisions of the Private Securities
Litigation Reform Act of 1995.
Contact:
Investor Relationsir@qlgntx.com.Source: Qualigen Therapeutics,
Inc.
Qualigen Therapeutics (NASDAQ:QLGN)
Historical Stock Chart
From Dec 2024 to Jan 2025
Qualigen Therapeutics (NASDAQ:QLGN)
Historical Stock Chart
From Jan 2024 to Jan 2025